News
2023
Date:
03 Apr,2024
In January, we were honored to be listed among the "Top 20 Industrial Enterprises in Wenling for 2022," ranking second on the list.
In January, we obtained the Indian registration certificate for cimetidine.
In February, it was honored with the title of "2022 Zhejiang Province Anti-Drug Model Unit for Integrity."
In February, the company was named on the "Zhejiang Province Industry-Education Integration Enterprise List for 2021–2022."
In February, the patent titled "Method for Determining the Content of Flavonol Glycosides in Ginkgo Leaf Droplets," application number 20211063404685, was granted.
In March, the company won two major awards: "2021 Outstanding Brand Enterprise in Chinese National Medicine" (with its flagship product, Ginkgo Leaf Droplets) and "2021 Top 50 Fast-Growing Companies in China's Pharmaceutical Industry."
In March, the company was proudly listed among the "Top 100 Traditional Chinese Medicine Enterprises of 2022," ranking 65th—up 22 places from last year.
In April, the "Huperzine A Injection Medical Research and Exchange Symposium," hosted by the National Clinical Research Center for Neurological Diseases and organized by Wanbangde Pharmaceutical Group, was successfully held.
In May, Wanbangde Pharmaceutical Group Co., Ltd. was listed on the independent innovation brand ranking with a brand strength of 713 and a brand value of 1.719 billion yuan, placing 12th overall.
In May, a university-enterprise-local government research collaboration agreement was signed with the School of Pharmaceutical Sciences at Zhejiang University.
From May to June, the postdoctoral research workstation picked up momentum, welcoming three newly appointed PhDs and adding fresh talent to our scientific research efforts.
In June, the company’s flagship product, Wanbang Xinnuokang® Ginkgo Leaf Dropping Pills, was featured on the "2023 China Pharmaceutical Brand List—Hospital Terminal Ranking: Cardiovascular and Cerebrovascular Disease Medications (Traditional Chinese Medicine)" category.
In June, the company was recognized as a four-star enterprise in the "2022 Taizhou City Enterprise Management Star Rating Evaluation."
In June, "Key Technology Development and Demonstration Application of Network Pharmacology" was awarded the Second Prize in the Science and Technology Progress category of the 2022 Ministry of Education Higher Education Outstanding Scientific Research Achievement Award.
In July, the company won two major awards: "Top 100 Chinese Pharmaceutical Manufacturers 2022-2023" and "Top 50 Fast-Growing Companies in China's Pharmaceutical Industry 2022-2023."
In July, the invention patent received the "24th China Patent Excellence Award" (Patent Title: A Fluorescent Probe with Aggregation-Induced Emission Properties, along with Its Preparation Method and Applications).
In August, the Academician and Expert Workstation successfully held a seminar on Huperzine A Controlled-Release Tablets and Huperzine A Injection, providing clear guidance for the product’s clinical trials and future research planning.
In October, it was recognized as one of Zhejiang Province's "Second Batch of Key Provincial Academician Workstations," and it is the only one in Taizhou.
In November, we successfully hosted the 19th Taizhou Pharmaceutical Regulatory Salon, themed "Standardized Development of the MAH Pharmacovigilance System."
In November, the company was listed among the "Top 500 Zhejiang Provincial High-Tech Enterprises in Innovation Capability," climbing 34 places up the rankings compared to last year.
In November, we were honored with the title of "2023 Taizhou City-Level Green Factory."
In November, the QC group's achievement, "Improving the Qualified Rate of Finished Huperzine A Injection," won the "Third Prize for Outstanding QC Achievements in Zhejiang Province."
In November, the company earned multiple honors, including the second-place team award and the first-place individual overall physical fitness title at Taizhou City's inaugural Emergency Rescue Skills Competition for Employees of Hazardous Chemical Enterprises.
In December, the company's flagship product, the acetylcholinesterase inhibitor [Huperzine A], received FDA Orphan Drug Designation for the treatment of myasthenia gravis.
Related Recommendations